Filter By Category
Archives
Share on -
EXARAFENIB
Generic Name: EXARAFENIB
ABSTRACT -
Exarafenib is a kinase-inhibitor API associated with RAF/MAPK pathway blockade in oncology development. It is a conventional small molecule, but the exact structure should be confirmed against a chemical database before final regulatory use.
DOSAGE -
Oral oncology dosing, when studied, is protocol-specific and adjusted for toxicity, hepatic function, and drug interactions.
SIDE EEFECTS -
- Rash or photosensitivity
- Diarrhea, nausea, or decreased appetite
- Fatigue
- Elevated liver enzymes
- Hypertension or cardiac effects may require monitoring
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require medical attention.
- Rash, urticaria, angioedema, bronchospasm, or anaphylaxis
DRUG INTERACTIONS-
- Strong CYP3A inhibitors or inducers may change exposure for many kinase inhibitors
- QT-prolonging drugs may require ECG review if applicable
- Avoid grapefruit products unless labeling permits
PREAUTONS–
- Check baseline liver function, blood pressure, ECG when indicated, and concomitant medicines
- Monitor dermatologic and ocular symptoms
- Embryo-fetal risk precautions are usually required for anticancer kinase inhibitors
WARNINGS –
- Severe cutaneous, hepatic, cardiovascular, or ocular toxicity can occur with kinase inhibitors
- Do not use without oncology protocol or label guidance
Share on -
. Developed by